Tweet
Have they gone the way of Helicos?
-
-
Too early to say. They could be just re-positioning the emphasis of their workforce. But paring down the work force of a supposedly growing company is rarely a good sign. Glad I didn't apply for any of those numerous PacBio posts in the "Industry Jobs" section. :-) -
Many are supposed to be in the "R&D" section, which is probably not good news either.Comment
-
They did go on a gangbuster hiring spree prior to their IPO, and are probably discovering that the revenue cannot support the workforce expansion. With their main strength relative to the competition being long segment reads, it is a valid question to ask whether there is a sustainable commercial position there. After all, how much denovo sequencing is needed on a large scale? On the surface GNOM would appear to be targeting a more sustainable commercial target. Thoughts?Comment
-
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...04-22-2024, 07:01 AM -
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...04-04-2024, 04:25 PM
Comment